Dynavax reports Phase Ib/II head and neck cancer data for TLR9 agonist combo

Dynavax Technologies Corp. (NASDAQ:DVAX) reported interim data from 18 evaluable patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in the Phase Ib/II MEL-01 (KEYNOTE-184) trial showing that SD-101 plus PD-1 inhibitor Keytruda pembrolizumab led to an objective response rate (ORR) of 33%. Median time to response was 64 days. Data were presented at the American Association for Cancer Research meeting in Chicago. SD-101 is an immunostimulatory sequence (ISS)-based second generation type C toll-like receptor 9 (TLR9) agonist...